The CVCA's February 2026 annual report puts Canadian venture capital at $8 billion across 571 deals in 2025. That number is technically accurate. It is also doing an enormous amount of work to hide a compression story that should worry anyone writing a seed-stage cheque in Vancouver right now.
The 26 Deals That Ate the Market
Strip out the 26 megadeals — rounds of $50 million or more — and the math gets uncomfortable fast. Those 26 transactions pulled in $5.3 billion, or 66% of all 2025 VC dollars, per CVCA data reported by BetaKit in February 2026. That leaves 545 deals splitting roughly $2.7 billion. Under $5 million average per deal. That is not a healthy early-stage market. That is a market where Series A and B rounds are getting quietly squeezed while a single firm — Toronto's Radical Ventures — raised $1.753 billion across two funds and statistically redefined what "Canadian VC fundraising" looks like in aggregate.
For context: historically, megadeal concentration in Canadian VC ran around 40 to 50 percent by dollar value through the 2018–2020 period. The 2021 boom temporarily masked the structural dependency by inflating deal counts across all stages. What 2025's 66% concentration actually reflects is a reversion — accelerated — to a market that was always propped up by a small number of anchor transactions. The CVCA's $8 billion figure is not wrong. It is strategically misleading in the same breath.
ICT Wins; Life Sciences and Cleantech Get Left Behind
ICT startups — the category that captures most AI companies — pulled in approximately $5 billion in 2025, close to 63% of all VC investment, according to CVCA data reported by The Logic. That concentration is real and not going away. US crossover funds with AI mandates are not going to start writing Series B cheques into Canadian biotech because a federal budget document asked nicely.
The sectors that bore the cost of that concentration:
- Life sciences VC dropped 47% year-over-year to $837 million in 2025, per CVCA via The Logic.
- Cleantech fell from roughly $1.2 billion in 2024 to $660 million in 2025, per the same CVCA annual report.
- Zero IPOs completed in Canada in 2025. Twenty-nine M&A exits total.
The life sciences collapse deserves more alarm than it's getting. Three years ago, the same "sector rotation into AI" framing was used to explain away biotech softness in the US — and it took 18 months before the honest read emerged: LP bases had simply repriced risk in anything with a 10-to-15-year development timeline. Canadian life sciences does not have the NIH backstop that US peers rely on. The enhanced SR&ED program — the CCPC expenditure limit raised to $6 million effective April 1, 2026, per the Government of Canada's Budget 2025 — improves the R&D incentive picture. But incentives do not replace equity capital when funds are chasing AI multiples.
Venture Debt at $1.4 Billion Is Not a Sophistication Story
The CVCA reported that venture debt hit a record $1.4 billion in 2025, with Q4 alone setting a quarterly record at $679 million. The coverage framed this as maturation of the Canadian market. That framing is wrong.
When founders are taking on non-dilutive debt at record rates in a zero-IPO, 29-M&A-exit environment, they are not optimizing their cap tables. They are buying time. The exit market is frozen. Capital recycling has effectively stopped. The LP base that would normally reinvest distributions into new Canadian funds is sitting on unrealized positions from 2021 and 2022 vintages that have not marked down honestly yet.
A senior partner at a Vancouver-based early-stage fund, who asked not to be named ahead of a live fundraise, put it plainly: "The debt numbers look like confidence. What they actually look like from inside a portfolio is founders extending runway because there is nowhere to go."
That debt reckoning is coming. Covenant deadlines will hit frozen exit conditions simultaneously in 2026 and 2027. Watch for that.
BC's $938M Ranking Conceals a Concentration Risk
British Columbia attracted $938 million in VC investment in 2025, ranking second nationally behind Ontario's approximately $2.6 billion, per the CVCA's Q3 2025 Market Overview. The provincial government has leaned into that number. BC's Budget 2025 raised the annual venture capital tax credit budget from $38.5 million to $53.5 million and increased the maximum individual investor tax credit from $120,000 to $300,000. Both moves are genuinely useful at the angel stage.
But angels writing $300,000 cheques do not solve a $5-to-$15-million gap-round problem. And BC's second-place national ranking is structurally more fragile than the dollar figure implies.
Ontario's $2.6 billion is anchored by Toronto's density of financial services infrastructure, US fund offices, and a university commercialization pipeline — MaRS, Waterloo — that BC does not replicate at scale. Vancouver's ecosystem is weighted toward enterprise software, gaming adjacencies, and resource-tech. It lacks the biotech cluster depth of Montreal or the fintech density of Toronto. InBC Investment Corp., the provincial government's VC arm, is sitting on a maturing legacy portfolio and has not signalled a dramatic deployment acceleration in its 2025–26 Service Plan. When the next sector rotation happens, BC's concentration risk is higher than its national ranking implies.
Vanhub Intelligence: Local Impact Analysis
According to recent market trends in Metro Vancouver, the two-tier compression story buried inside Canada's 2025 VC numbers has a direct read-through to the region's tech employment base — and by extension, to the residential absorption patterns that prop up everything from Burnaby's Brentwood corridor to East Vancouver's rental conversion market. Vancouver's startup ecosystem punches below its weight in megadeal territory. The city has not produced a Radical Ventures-scale fund anchor, and the practical consequence is that seed and Series A companies here are competing for a shrinking slice of that $2.7 billion non-megadeal pool. When early-stage capital compresses nationally, the first casualty is headcount growth at the sub-50-employee companies that have historically filled the Class B office inventory along Broadway and in the False Creek Flats tech district. Downtown Vancouver office vacancy was already running at elevated levels through 2024 and into 2025 — recent Metro Vancouver data suggests the tech sub-leasing cycle has not fully cleared — and a sustained early-stage funding drought will extend that timeline. Fewer funded startups means fewer lease signings, which means the office-to-residential conversion pressure that City of Vancouver planners have been quietly managing under the Broadway Plan and the broader Bill 44 upzoning framework becomes simultaneously more urgent and harder to finance.
For Vancouver homeowners and renters, the calculus is more indirect but not negligible. The Cascadia tech corridor — the pipeline of mid-career engineers and product managers moving between Seattle, Bellevue, and Vancouver — is sensitive to funding cycles in ways that local housing demand models tend to underweight. When US crossover funds concentrate on megadeals and Canadian seed rounds dry up, the relocation incentive for tech talent to choose Vancouver over a Seattle suburb weakens. That matters for the condo presale market in Burnaby's Metrotown and Lougheed SkyTrain nodes, where developer pro formas have been quietly underwritten against continued tech-sector in-migration. BC Assessment values in those corridors have held relatively firm, but Given the current BC assessment climate and the stress-test threshold still sitting above 7% on most insured refinances, any demand-side softening from tech employment slowdowns will arrive at exactly the wrong moment for owners carrying variable-rate mortgages originated during the 2021–2022 peak.
Vanhub Editorial Staff notes: the life sciences collapse is the number that Vancouver's economic development community should be losing sleep over, and largely isn't. Metro Vancouver operators should note that the 47% year-over-year drop in Canadian life sciences VC is not an abstraction — it is a direct funding environment signal for the cluster of biotech and genomics companies anchored around UBC's University-Blvd corridor, the Centre for Drug Research and Development, and the broader False Creek South life sciences precinct that the City has been trying to densify under its rezoning agenda. These companies do not benefit from the AI multiple compression that is driving capital toward ICT megadeals. They operate on 10-to-15-year development timelines, they are disproportionately reliant on follow-on Canadian VC rather than US crossover participation, and the enhanced SR&ED expenditure limit — effective April 1, 2026 — improves their R&D cost structure at the margin but does not replace the equity rounds that have simply stopped materializing. The BC speculation and vacancy tax creates a secondary pressure point: researchers and clinical-stage founders who might otherwise relocate to Vancouver to join these companies are running a housing cost calculus that makes the city structurally expensive relative to comparable biotech hubs in the US mid-tier.
The zero-IPO year and the 29 M&A exits nationally tell the liquidity story that the $8 billion headline obscures. In Vancouver terms, that means the carried-interest recycling that would normally flow back into local angel networks and seed funds — the mechanism by which a successful exit at one company seeds the next generation of founders — is running at near-zero velocity. This is the recycling problem the article's headline names but that local policy has not yet seriously addressed. The Metro Vancouver Regional District's growth plans are calibrated around continued knowledge-economy job creation in the Broadway and Surrey City Centre corridors. If the VC funding structure that underwrites that job creation is quietly bifurcating into megadeal winners and everyone else, the land-use assumptions embedded in those plans deserve a harder look than they are currently getting from either City Hall or the development community.
The Federal $1.75 Billion Bet and What It Can't Fix
Federal Budget 2025 commits $1 billion over three years to BDC Capital's new Venture and Growth Capital Catalyst Initiative — a fund-of-funds targeting pension and institutional co-investment — plus a further $750 million for early-growth-stage firms, with strategy details still to be announced in 2026, per the Department of Finance.
The intent is clear: reverse the collapse in domestic VC fundraising, pull pension capital off the sidelines, and give Canadian GPs the anchor commitments they need to lead deals rather than follow US funds. The 60% US investor participation rate in 2025 — the highest share since 2017, per CPE Analytics and RCG data from March 2026 — is the specific problem this policy is trying to address. When US parties lead or co-lead the majority of Canadian VC dollars, Canadian GPs build track records as syndicators, not lead investors. That affects their ability to raise independent funds from institutional LPs who want conviction-led deployment.
The honest counterpoint: the last time the federal government ran a major fund-of-funds intervention — the 2013 Venture Capital Action Plan — it took four years to show measurable impact on deal flow metrics. BDC's new mandate is better structured, but the question a skeptical LP committee would ask is whether the $1.75 billion is patient enough to wait for the 2028–2030 window when current portfolio companies actually need growth capital, or whether political pressure forces premature deployment into the same overvalued late-stage deals already crowding the market.
The CVCA's headline number says $8 billion. The structure underneath it says something different. Canada's VC market is bifurcating — 26 deals at the top, a squeezed middle, and a recycling problem that federal policy is about to spend $1.75 billion pretending is primarily a supply problem. Whether that bet lands will show up in the 2027 annual report. The founders trying to close a $10 million round in Vancouver right now do not have that long to wait.
